Clinical Trials

Interleukin-12 Cancer Trial Halted After Patient Dies

Published in Gene Therapy Weekly, July 3rd, 1995

A multicenter study of Interleukin-12 (IL-12) was halted while researchers tried to determine why one patient died and 11 more were hospitalized with "adverse reactions."

IL-12 is a naturally occurring cytokine that is genetically engineered and produced by Genetics Institute Inc. (GI), of Cambridge, Massachusetts. IL-12 has shown promise as a treatment for cancer, AIDS, tuberculosis, and malaria, and was being clinically tested in a trial of kidney cancer patients.

The multicenter study was put on hold June 8, 1995, when two of seventeen patients were hospitalized. According to a news story in Science (June 16, 1995;268(5217):1555), one of the two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry